Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment…
Search results for: pain
Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib
NEW YORK (Reuters Health)—Ibuprofen boosts blood pressure (BP) more than naproxen or celecoxib in patients who take non-steroidal anti-inflammatory drugs (NSAIDs) to treat arthritis, according to a new substudy from the PRECISION trial. “These drugs are different with regard to BP, and ibuprofen is the worst,” Dr. Frank Ruschitzka of University Hospital Zurich in Switzerland,…
Medication Adherence for Osteoporosis Prevention
In a new study, patients taking denosumab had greater treatment adherence over two years than patients on alendronate and other anti-osteoporosis agents…
U.S. Senator Reveals Results of Opioid Inquiry into Insys
BOSTON (Reuters)—Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday. The report, released by Democratic Senator Claire McCaskill, said those efforts led to an Insys employee making misleading statements…
High Prevalence of Kingella Kingae in Children with Joint Infections
NEW YORK (Reuters Health)—Oropharyngeal carriage of Kingella kingae is strongly associated with osteoarticular infection in young children, a case-control study done from Canada and Switzerland shows. “Most of the kids who have osteoarticular infection with Kingella kingae will also have it in their throat, so if we do a throat swab, we can identify it…
ACR/ARHP Makes Another Push to Repeal Medicare Therapy Caps
H.R. 807, Medicare Access to Rehabilitation Services Act of 2017, will be one of the key issues discussed when members of the ACR’s Government Affairs Committee (GAC) visit Capitol Hill Sept. 26 during the annual Advocates for Arthritis event. This bill—as well as its companion bill in the Senate, S. 253—is aimed at repealing the…
Arizona Accuses Insys of Fraudulent Opioid Marketing Scheme
(Reuters)—Arizona’s attorney general sued Insys Therapeutics Inc on Thursday, accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine. The lawsuit by Arizona Attorney General Mark Brnovich in Maricopa County Superior Court in Phoenix comes during a series of federal and state investigations centered on…
Opioid Use in U.S. RA Patients
Nationally, opioid use and addiction are drawing increased scrutiny. An increase in the number of overdoses and addiction to heroin and prescription pain relievers in the past decade has been attributed in part to increased prescribing of opioids for the treatment of pain by physicians. National trends suggest the rate of opioid prescribing plateaued in…
New SLE Criteria Under Development: A Joint Effort of the ACR & EULAR
MADRID—Systemic lupus erythematosus (SLE) experts in North America and Europe are working together to refine the classification system for the disease, with the goal of producing a new set of criteria that is simpler to use and more scientifically rigorous than any classification approach previously published, speakers involved with the process said at the 2017…
Flimsy Evidence Behind Many FDA Approvals
(Reuters Health)—Many drugs granted accelerated approval by the U.S. Food and Drug Administration (FDA) lack clear evidence of safety and effectiveness, and the same is true for most high-risk medical devices, according to two new reports in JAMA, online Aug. 15. The Accelerated Approval pathway makes potentially promising investigational medicines available for use before the…
- « Previous Page
- 1
- …
- 131
- 132
- 133
- 134
- 135
- …
- 245
- Next Page »